Skip to main content
No. of Recommendations: 21
ZM and other WFH stocks were up significantly in early pre-market trading when this news broke:

"The first interim efficacy analysis of the large-scale Phase 2/3 clinical trial evaluating Pfizer (NYSE:PFE) and BioNTech's (NASDAQ:BNTX) COVID-19 vaccine candidate, BNT162b2, showed it to be more than 90% effective seven days after the second dose in preventing infection in participants with no evidence of prior SARS-CoV-2 infection."

Almost immediately prices started declining, and as I write (~7:30am) ZM is -12%, DOCU -8% and TDOC -5%. Other SaaS stocks show collateral damage. This is a premature reaction on very preliminary data, and likely a buying opportunity.
Print the post  


What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.